The expression of estrogen receptor (ER) or progesterone receptor (PR) in tumor tissues has been shown to be positively correlated with the clinical outcomes in gynecological cancers including ovarian cancer, although this has been debated for many years due to study sample sizes and the influence of ethnicitic differences. Here, PGR is linked to neoplasm.